Type 2 Diabetes, Chronic Kidney Disease Stage 3
Conditions
Keywords
closed-loop, type 2 diabetes
Brief summary
The main objective of this study is to evaluate the effect of fully automated closed-loop glucose control on renal tissue oxygenation among people with type 2 diabetes and chronic kidney disease. This is a single-center, open-label parallel design study that will compare 26 weeks of fully-automated closed-loop glucose control with standard insulin therapy and continuous glucose monitoring, following a run-in period. A total of up to 76 adults with type 2 diabetes and chronic kidney disease will be recruited through outpatient diabetes and nephrology clinics. The primary outcome is renal tissue oxygenation measured using blood oxygenation level-dependent magnetic resonance imaging at 26 weeks. Other key outcomes include glycated hemoglobin at 26 weeks and time spent with glucose levels within and above the target glucose range (3.9-10.0mmol/L). Other glycemic and renal outcomes (including renal function) will also be assessed, as well as patient-reported outcome measures using validated questionnaires. Safety evaluations include severe hypoglycemic episodes and other adverse and serious adverse events.
Detailed description
Recruitment: The investigators aim to recruit 76 participants through the Service of Endocrinology, Diabetes, and Metabolism and through the Nephrology and Hypertension Service at the University Hospital of Lausanne (CHUV), as well as other outpatient diabetes clinics in the canton of Vaud if needed. Screening visit: Potential participants will have the opportunity to ask questions and will give written informed consent if interested in participating in the study. A screening blood test, a urine analysis, and urine pregnancy test will be done at this visit. Baseline visit: The baseline assessment will consist of a medical history, height and weight measurement, waist-hip ratio measurement and blood pressure measurement. Participants will also answer questionnaires to assess patient-reported outcome measures and undergo a renal MRI. A masked glucose sensor will be worn for 14 days. Visit 3: Randomisation will occur in a 1:1 ratio using REDCap to the use of fully closed-loop therapy or standard insulin therapy with continuous glucose monitoring (CGM) for 26 weeks once the participants complete the masked CGM period. Participants will attend the research center and receive training on study devices (closed-loop system or CGM) and study devices will be initiated. Visit 4: Participants will attend the research center around two days after initiation of the study arm to discuss potential issues related to use of study devices. This visit can also be conducted by phone. Telephone contacts: Participants in both arms will be contacted by telephone 1 week after initiation of the study arm, as well as at one, two, four, and five months after initiation of study arm to discuss any issues with devices, adverse events, or changes to medications. Visit 5 (3 month visit): Participants will attend the research center and fill-out questionnaires and a blood test and urine analysis will be performed. Visit 6 (6 month visit): Participants will attend the research center and fill-out questionnaires and a blood test and urine analysis will be performed. A renal MRI will be repeated at this visit. Study devices will be returned, and participants will resume their usual diabetes care. Patient-reported outcomes: Patient-reported outcome measures will be assessed using five validated questionnaires: Diabetes Distress Scale, Hypoglycemia Attitudes and Behavior Scale, Audit of Diabetes-Dependent Quality of Life, Diabetes Treatment Satisfaction Questionnaire - status version, Diabetes Treatment Satisfaction Questionnaire - change version Safety outcomes: Safety outcomes will include the number of severe hypoglycemia episodes, as well as the nature and severity of other adverse events including serious adverse events.
Interventions
DEVICECamAPS HX
The CamAPS HX fully closed-loop system consists of an insulin pump, a continuous glucose monitoring (CGM) sensor, as well as the CamAPS HX app, which resides on a smartphone and communicates wirelessly with the insulin pump.
Participants will continue their standard insulin therapy with a Freestyle Libre 3 CGM
Sponsors
Heba Al-Alwan
Swiss National Science Foundation, Switzerland
Institute of Primary Health Care (BIHAM), Switzerland
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent signed by the subject * Age 18 years and older * Type 2 diabetes diagnosed for at least 12 months * Treatment with insulin therapy for at least 6 months * CKD defined either as an eGFR 30-59 ml/min/1.73m² or presence of albuminuria \> 3 mg/mmol (stage A2 or A3 according to KDIGO) with an eGFR \> 30 ml/min/1.73m². CKD must be present for at least 6 months. * HbA1c \< 12% based on a venous blood sample from the screening visit * Receiving treatment with an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, have been offered these therapies previously, or contraindication/intolerance to receiving these therapies * Willing to wear study devices and follow study instructions * Capable of giving an informed consent
Exclusion criteria
* Type 1 diabetes * Current use of insulin pump * Current use of any closed-loop system * Alternative cause of CKD according to medical records such as polycystic kidney disease, glomerulonephritis, congenital urogenital tract diseases, etc. * Known or suspected allergy against insulin * Pregnancy, planned pregnancy, or breast feeding * Severe visual impairment * Severe hearing impairment * Two or more episodes of severe hypoglycemia in the last 6 months * Medically documented allergy towards the adhesive (glue) of plasters * Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor * Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician * Recent (less than three months) history of myocardial infarction, percutaneous coronary intervention, stroke, or hospitalization for heart failure with reduced ejection fraction * History of renal transplantation requiring ongoing immunosuppressive therapy * Known or suspected non-compliance, drug or alcohol abuse * Inability to follow the procedures of the investigation, e.g. due to language problems * Incapacity to give informed consent * Contra-indication to undergo MR-imaging according to a standard checklist such as the presence of a pacemaker or other implanted metallic device or severe claustrophobia. * Subject refuses to be informed of incidental findings related to their health discovered during imaging or other study-related exams * Participation in another investigation with an investigational drug or another MD within the 30 days preceding and during the present investigation * Previous enrolment into the current investigation * Enrolment of the PI, his/her family members, employees and other dependent persons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cortical renal tissue oxygenation (R2*) | at 26 weeks | Measured using BOLD-MRI |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of time spent in the target glucose range (3.9 to 10.0mmol/l) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Glycated hemoglobin | at 26 weeks | — |
| Proportion of time spent above target glucose (>10.0mmol/l) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Mean sensor glucose | over 26 weeks | Sensor glucose metric measured in mmol/l |
| Non-inferiority for time spent below target glucose (<3.9mmol/L) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Standard deviation of sensor glucose | over 26 weeks | Sensor glucose metric measured in mmol/L |
| Coefficient of variation of sensor glucose | over 26 weeks | Sensor glucose metric measured as a percentage |
| Proportion of time spent below target glucose (<3.5mmol/L) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Proportion of time spent below target glucose (<3.0mmol/L) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Proportion of time spent above target glucose (>13.9mmol/l) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Proportion of time spent above target glucose (>16.7mmol/l) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Proportion of time spent above target glucose (>20.0mmol/l) | over 26 weeks | Sensor glucose metric measured as a percentage |
| Per-kidney renal perfusion (ml/min) | at 26 weeks | MRI-assessed outcome |
| Kidney inflammation (T1, msec) | at 26 weeks | MRI-assessed outcome |
| Medullary renal tissue oxygenation (R2*) | at 26 weeks | measured using BOLD-MRI |
| R2* slope | at 26 weeks | measured using BOLD-MRI |
| Serum creatinine (umol/l) | at 26 weeks | — |
| Serum urea (umol/l) | at 26 weeks | — |
| Urine albumin/creatinine ratio (ACR) | at 26 weeks | — |
Countries
Switzerland
Contacts
CONTACTHeba Al-Alwan, MD, PhD
Outcome results
None listed